Poor response to clopidogrel: current and future options for its management

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Antiplatelet therapy, particularly clopidogrel, is crucial for managing acute coronary syndromes and percutaneous coronary interventions (PCI).
• A significant portion of patients (around 20%) exhibit poor or non-response to clopidogrel, impacting treatment efficacy.
• Assessing clopidogrel responsiveness is challenging due to a lack of standardized testing methods.

Purpose of the Study:

• To review the clinical impact of poor clopidogrel responsiveness.
• To explore the multifactorial mechanisms underlying clopidogrel non-response.
• To discuss current and future management strategies for patients with poor clopidogrel response.

Main Methods:

• Literature review of studies assessing clopidogrel responsiveness and clinical outcomes.
• Analysis of various assays used to measure antiplatelet effects.
• Examination of proposed mechanisms for poor responsiveness.
• Review of therapeutic interventions for non-responders.

Main Results:

• Poor responders to clopidogrel face elevated risks of mortality, myocardial reinfarction, and stent thrombosis.
• Mechanisms of poor response are multifactorial, including genetics, platelet turnover, P2Y(12) pathway issues, and drug interactions.
• Despite challenges in standardization, studies consistently link poor response to adverse clinical events.

Conclusions:

• Poor response to clopidogrel significantly worsens clinical outcomes in patients with atherothrombotic diseases.
• Understanding the mechanisms of non-response is key to developing effective management strategies.
• Therapeutic adjustments, such as dose escalation or switching agents, may improve outcomes for poor responders.